Trending...
- Joseph Neibich: Crafting Comedy from Hollywood Chaos
- Yonkers: MAYOR SPANO ANNOUNCES YONKERS FIRE DEPARTMENT SECURES LARGEST FEMA AFG GRANT IN NEW YORK STATE
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Arvinas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025."
More on Nyenta.com
On this news, Arvinas's stock price fell sharply during intraday trading on November 19, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether Arvinas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025."
More on Nyenta.com
- The Joy of Gifting Wine and Spirits!
- EnergyStrat Launches Global LNG Risk Outlook 2025–2030
- Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
- Loa Carbon Announces Appointment of Adam Goldstein to Board of Directors
- Holiday Decorations Most Likely to Cause Injuries
On this news, Arvinas's stock price fell sharply during intraday trading on November 19, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Rigani Press Announces Breakthrough Book for Health IT and Medical Leaders to Forge the Road to Responsible AI
- StoneZen Capital Consortium and Llewellyn Hawthorne Launch Infrastructure Upgrade
- FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
- Decks Profi Launches With Limited-Time Offer
- Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
- "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide
- DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide
- Who Plays Ally in Stranger Things Season 5?
- Evelyn Reed Releases New Emotional Memoir - Shattered Vows: A Journey Through Betrayal and Healing
- Accelerating Precious Metals Expansion and Digital Asset Innovation Ahead of 2026: Asia Broadband Inc. (Stock Symbol: AABB)
- "Some Days I Just Broke Down": The Overlooked Struggles Faced by Stem Cell Transplant Patients
- Chrome Angelz RC Announces 2026 International Convention in Cortland, New York
- Naturism Resurgence (NRE) Announces the World's First Standardised Stigma Measure (SSM) for Naturism
- NetConnect Appoints Industry Veteran Christopher Galati as Chief Operations Officer
- Greece: The Cradle of Civilization at the Crossroads of Higher Education
- London Art Exchange Emerges as a Leading Force in UK Contemporary Art, Elevating Three Artists to Secondary-Market Success
- 247Tasker Responds to Global AI Debate: "Human Skills Will Always Matter More Than Machines"
- Award-Winning Poet Jacob Harvey Redloh
- myLAB Box Expands, Becoming the First and Only At-Home Testing Company to Serve the Entire Family—Human and Furry—with New Pet Intolerance Test
- Entering 2026 with Expanding Footprint, Strong Industry Tailwinds, and Anticipated Q3 Results: Off The Hook YS Inc. (N Y S E American: OTH)